Diabetic ketoacidosis with sodium–glucose cotransporter type 2 inhibitors: a case series

Gina McLachlan, Claire Keith and Albert Frauman
Med J Aust 2019; 211 (5): . || doi: 10.5694/mja2.50302
Published online: 2 September 2019

To the Editor: Sodium–glucose cotransporter type 2 (SGLT2) inhibitors — dapagliflozin, empagliflozin and now ertugliflozin — have become established second line options for type 2 diabetes, with favourable potential for weight loss and cardiovascular protection.1 However, it soon became clear post‐marketing that they had potential for several pronounced side effects, including euglycaemic ketoacidosis — an unusual form of diabetic ketoacidosis where blood sugar levels remained relatively normal.2

  • Gina McLachlan1
  • Claire Keith1
  • Albert Frauman1,2

  • 1 Austin Health, Melbourne, VIC
  • 2 University of Melbourne, Melbourne, VIC

Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.